140 filings
Page 6 of 7
6-K
xminld7udj
14 Sep 21
Current report (foreign)
8:32am
6-K
x5a q7xxbi
9 Sep 21
Medicenna Therapeutics to Present at Upcoming September Investor Conferences
9:05am
6-K
zmus3n iclrwbtqxnr
1 Sep 21
Current report (foreign)
8:00am
6-K
enfxo4u
13 Aug 21
Interim condensed consolidated financial statements of
7:10am
6-K
dwm2fl
4 Aug 21
Current report (foreign)
9:20am
6-K
inbcbwi63v cm
27 Jul 21
Medicenna Announces That Initiation of MDNA11 Phase 1/2 Study is on Track; Update to be Provided at the PropThink Digital Conference
10:49am
6-K
6kscd
14 Jul 21
Current report (foreign)
9:41am
6-K
g1l6alcxm2n rje9l
23 Jun 21
Medicenna Announces Submission of Clinical Trial Application in Australia for a Phase 1/2 Study of MDNA11
9:15am
6-K
p37ybm0
28 May 21
Medicenna Reports Fiscal Year 2021 Financial Results and Operational Highlights
7:40am
6-K
44g sj2m25c1k
20 May 21
Current report (foreign)
9:10am
6-K
iapdbn5swey
12 May 21
Medicenna Appoints Immuno-Oncology Expert Dr. Mann Muhsin as Chief Medical Officer
9:10am
6-K
c233n4lbv9m
7 May 21
Medicenna Announces the Peer-Reviewed Publication of Clinical Data from Phase 2b Trial Evaluating MDNA55 in Recurrent Glioblastoma
10:04am
6-K
m70f6h2 as0t0za52yn7
21 Apr 21
Medicenna Therapeutics Announces the Appointment of Industry Veteran, Kevin Moulder, PhD, as Chief Scientific Officer
9:56am
6-K
nd9sq47fo6n568s h9ea
14 Apr 21
Medicenna to Present at the Bloom Burton & Co. Healthcare Investor Conference
9:05am
6-K
g5gaty
12 Apr 21
Current report (foreign)
7:05am
6-K
2bmalplv4buu9t2qbwmy
25 Mar 21
Current report (foreign)
8:07am
6-K
tck1l sx4o0z7wy
11 Mar 21
Medicenna Therapeutics Announces Upcoming Presentation at the AACR Annual Meeting 2021
7:15am
6-K
47cp4
4 Mar 21
Medicenna Therapeutics to Present at Upcoming March Investor Conferences
7:30am
6-K
pe0l5syevg gejw2zk
22 Feb 21
Medicenna to Present at the Cowen 41st Annual Healthcare Conference
7:15am
6-K
f9u3tgk
17 Feb 21
Medicenna to Present at the 10th Annual SVB Leerink Global Healthcare Conference
9:01am